Organoid > Volume 3; 2023 > Article |
|
Purpose of co-culture |
Co-culture |
Type of in vitro platform used | Effect of co-culture | Ref. | |
---|---|---|---|---|---|
Adipocytes | Other cell types | ||||
To induce obese micro-environment | 3T3-L1 | BMDMs and ATMs | Transwell plate (0.4 μm pore) | 6-fold increase in miR-223 abundance. | [49] |
Several fold increase in ATM-derived miR-223 expression. | |||||
3T3-L1 | RAW 264.7 | Transwell plate (0.4 μm pore) | Mimicking obesity-related inflammation with lipopolysaccharide stimulation. | [50] | |
Identification of riboflavin pro-inflammatory activity inhibitory effect. | |||||
3T3-L1 | RAW 264.7 | Transwell plate (0.4 μm pore) | Improvement of the induction of various inflammatory responses observed in an obese environment. | [51] | |
3T3-L1 | RAW 264.7 | Transwell plate | Increased ANGPTL2 mRNA expression. | [52] | |
MMP9 mRNA upregulation. | |||||
Identification of pathways that cause inflammation in adipocytes and immune cells. | |||||
3T3-L1 | RAW 264.7 | Transwell plate | Reproduction of the adipose microenvironment. | [53] | |
Verification of anti-inflammatory effects of SO1989. | |||||
PHA and SGBS preadipocytes | THP-1 | Transwell plate (0.4 μm pore) | Identification of the role of IL-29 as a regulator. | [54] | |
To recapitulate the interaction between BC cells | 3T3-L1 | BC cells (MDA-MB-231, MCF7, SUM159, or Hs578t) | 3D co-culture system with Matrigel | Breast tissue reproduction. | [55] |
More accurate analysis of EMT and MET | |||||
3T3-F442A and PHA | BC cells (MDA-MB-436 and E0771) | Transwell plate (0.4 μm pore) | The increased expression of MVP. | [56] | |
Induction of MVP-related multidrug resistance phenotype in BC cells by adipocytes. | |||||
Murine fat tissue or PMA | BC cell (MDA-MB-231) | Transwell plate (0.4 μm pore) | Increased expression of inflammation-related genes in co-culture of adipocytes. | [57] | |
PHA | CC cells (PT130 and SW480) | Transwell plate | Increased CPT1A expression. | [58] | |
Increased survival of CC cells. | |||||
Identification of CPT1A, a key regulator of metabolism carried by adipocytes in CC cells. | |||||
PHA | CC cell (PT93) | Transwell plate | Transfer of free fatty acids that were released from adipocytes to the CC cells. | [59] | |
Induction of CC cell autophagy by AMPK activation of adipocytes. | |||||
PHA | GC cells | Transwell plate | Reduced anoikis | [60] | |
Elevated CD36 and its transcription factor in GC cells. | |||||
Higher basal and maximal respiration rates and higher intracellular ATP levels by adipocytes | |||||
mADSC, preadipocytes, or primary mesothelial cells | OC cell (A224) | Transwell plate (0.4 μm pore) | Reduction of pyruvic acid and lactic acid production in OC cells by adipocytes | [61] | |
Mediation of the growth inhibitory effect of ITLN1 on OC cells of mature adipocytes. | |||||
3T3-L1 | LC cell (A549) | Ad-CM and transwell plate (0.4 μm pore) | A549 cells induced adipocyte lipolysis. | [62] | |
Adipocytes altered energy metabolism, particularly in LC cells through glycolysis. |
BMDMs, bone-marrow-derived macrophages; ATMs, adipose tissue macrophages; SGBS, Simpson-Golabi-Behmel syndrome; BC cells, breast cancer cells; CC cells, colon cancer cells; GC cells, gastric cancer cells; OC cell, ovarian cancer cell; PHA, primary human adipocytes; PMA, primary murine adipocytes; mADSC, mature adipocytes differentiated from adipose-derived stem cells; LC cell, lung cancer cell; Ad-CM, conditioned medium from adipocytes; ANGPTL2, angiopoietin-like protein; MMP9, matrix metalloproteinase-9; IL-29, interleukin-29; EMT, epithelial-to-mesenchymal transition; MET, mesenchymal-to-epithelial transition; MVP, major vault protein; CPT1A, carnitine palmitoyltransferase I; AMPK, AMP-activated protein kinase; ATP, adenosine triphosphate; ITLN1, intelectin1.
Technology used | Cell type | Cell culture specificity | Total culture period | Function evaluated | Ref. |
---|---|---|---|---|---|
Extrusion-based 3D printing | Human ASCs | GelMA and CarMA | Day 14 | Cell viability | [63] |
Adipogenic differentiation ability | |||||
ASCs/HUVECs co-culture spheroids | GelMA | Day 7 | Adipogenic differentiation and ◦vascularization | [64] | |
MCF-7 and ADSCs | Blend of alginate and gelatin | Day 10 | Optimization of co-culture with MCF-7 and ADSCs | [65] | |
Adipogenic differentiation | |||||
Human preadipocyte cells and HUVECs | Adipose tissue- and aortas-dECM | Week 4 | Adipogenic differentiation and vascularization | [66] | |
In vivo volume retention | |||||
Integration with host tissue with neovascularization in artificial tissue | |||||
3T3-L1 | Crosslinked gelatin hydrogels | Day 14 | Direct cytocompatibility | [67] | |
Adipogenic differentiation | |||||
ADMSCs, 3T3-L1 and RAW264.7 | Alginate, gelatin, and collagen | Day 12 | Adipogenic differentiation | [26] | |
Changes of insulin resistance | |||||
Drug screening | |||||
Human bone marrow MSCs | GelMA | Day 8 | Adipogenic differentiation | [68] | |
Spatial distribution of cells and lipid droplets in scaffolds | |||||
Microfluidics | 3T3-L1 | PDMS chip that can connect with MS | Day 13 | Monitoring secreted metabolites with MS detection | [69] |
3T3-L1 and J774A.1 | Integrated adipose-tissue-on-chip nanoplasmonic biosensing platform | Day 15 | Adipocyte differentiation, maturation, and inflammatory stimulation | [70] | |
Cytokine detection | |||||
Visceral adipose tissue | PDMS on-chip tissue culture platform | Day 6 | Tissue viability and morphology | [71] | |
Biopsy culture | Patient-specific glucose uptake detection | ||||
Insulin sensitivity | |||||
ASCs, HUVECs and NHLFs | Fibrinogen | Day 10 | Adipogenic differentiation and vascularization | [36] | |
Microfluidic device consisting of 5 cell culture chambers flanked by 2 fluidic channels | Vascularized adipose tissue | ||||
Primary murine preadipocytes | A dual-layer, membrane-based microfluidic devices | Day 14 | Adipogenesis. | [72] | |
Insulin resistance (lipid droplet, glucose uptake and western blot and Glut-4 localization) | |||||
Lipid metabolism | |||||
PMA | Collagen | - | Adipocyte culture | [73] | |
PDMS chip with a reservoir for adipocyte capture | Adiponectin secretion for sampling | ||||
Human preadipocytes and U937 | Si-based microfluidic chip with 3 main features | Day 20 | Adiponectin and IL-6 secretion | [74] | |
- Concentric cell culture compartments | Insulin resistance by glucose uptake | ||||
- Microchannel arrays | |||||
- Media channels | |||||
Human preadipocytes | Cytoarchitecture on the chip with fiber networks | Day 83 | Adipogenesis. | [75] | |
Adipocyte hypertrophy | |||||
Functional responses to simulated meals and fasting | |||||
PHA | Collagen | Day 47 | Validation of adipocyte functionality; glucose and fatty acid metabolism | [76] | |
Tailored microfluidic platform | Long-term functionality | ||||
- 3D-tissue chambers | Drug test with isoproterenol | ||||
- Perfusable microchannels | |||||
PBMCs and PHA | Microfluidic chip separated by porous membrane. | Day 14 | Adipocyte differentiation | [25] | |
- Lower part: 2 fluidic compartments | Immune-metabolic analysis | ||||
- Upper part: adipocytes/immune cells culture |
3D, 3-dimensional; ASC, adipose tissue-derived stem cells; HUVEC, human umbilical vein endothelial cells; ADSCs, adipose-derived stromal cells; MSCs, mesenchymal stromal cells; ADMSCs, adipose-derived mesenchymal stem cells; PBMCs, peripheral blood mononuclear cells; NHLFs, normal human lung fibroblasts; GelMA, methacrylamide-modified gelatin; CarMA, methacrylate-modified κ-carrageenan; dECM, decellularized extracellular membrane; PDMS, polydimethylsiloxane; MS, mass spectrometry; Glut-4, glucose transporter type 4; IL-6, interleukin-6.
Heejeong Yoon
https://orcid.org/0000-0002-1695-9692
Tae-Eun Park
https://orcid.org/0000-0003-3979-5405